14.3 Contraception, Fertility Assessment, and Irish Termination of Pregnancy Law
Key Takeaways
UKMEC 2025 is a named UK eligibility reference. Category 4 identifies an unacceptable health risk. Examples for combined hormonal contraception include current migraine with aura, age 35 or older with smoking at least 15 cigarettes per day, and clinic blood pressure at or above 160 systolic or 100 diastolic.
Avoid assuming that all progestogen methods have the same eligibility. DMPA differs from the implant, POP and LNG-IUD in VTE risk and may lower bone density and delay return of fertility. Check Irish product indications and current HPRA warnings.
A copper IUD is the most effective emergency contraception and can work after ovulation. For a timing or eligibility question, seek prompt advice from an Irish fitting service, especially with multiple exposures or uncertain ovulation.
Ulipristal 30 mg is authorised within 120 hours of unprotected sex, and levonorgestrel 1.5 mg within 72 hours. Recent enzyme inducer use changes the choice. The FSRH clinical approach delays hormonal contraception for five days after ulipristal and then uses method-specific back-up.
Under Section 12 of the Irish 2018 Act, at least three days must elapse from the date of certification and the pregnancy must not have exceeded 12 weeks. Section 22 requires prompt transfer arrangements where a clinician objects and preserves emergency duties under Section 10.
Method-specific contraceptive eligibility
Start by asking what the patient wants from contraception, including bleeding pattern, daily use, return to fertility and STI protection. Check possible pregnancy, medication interactions, migraine history, blood pressure when considering combined hormonal contraception, thrombotic risk and relevant postpartum or medical history. Discuss condoms for STI risk alongside any other method. The HSE Free Contraception Service covers approved options and associated appointments and procedures for eligible people aged 17–35 who live in Ireland, including oral emergency contraception and emergency copper IUD fitting.
Interpreting medical eligibility
The College of Sexual and Reproductive Healthcare's UKMEC 2025 is a UK clinical reference. The category is for a particular method and clinical condition, sometimes with different rules for starting and continuing. Check Irish product information and applicable local guidance as well.
| Category | Meaning |
|---|---|
| 1 | No restriction due to this condition |
| 2 | Benefits generally outweigh known or theoretical risks |
| 3 | Risks generally outweigh benefits. Consider alternatives, with specialist input if a usual alternative is inappropriate or unacceptable. |
| 4 | Unacceptable health risk for this method under the framework |
Combined hormonal contraception (CHC)
The pill, patch and ring deliver an oestrogen and a progestogen. The main contraceptive action is suppression of ovulation. They can also help with cycle control and dysmenorrhoea. The oestrogen component makes vascular risk assessment especially important.
- Migraine: UKMEC 2025 assigns CHC category 4 for migraine with aura. It lists a separate category 3 for a history of aura at least five years ago. Establish whether the visual symptoms are genuine aura and check the individual medicine's contraindications.
- Smoking and blood pressure: Age at least 35 with at least 15 cigarettes daily is category 4. Fewer than 15 cigarettes daily at that age is category 3. Clinic systolic pressure at least 160 mmHg or diastolic pressure at least 100 mmHg, and vascular disease due to hypertension, are category 4.
- VTE: History of VTE or current VTE on anticoagulation is category 4 for CHC in UKMEC 2025. Any exceptional continuation while anticoagulated is a specialist decision. Confirm thrombophilia and other vascular contraindications separately.
- Postpartum: CHC is category 4 in the first six weeks if breastfeeding. If not breastfeeding, review time since delivery and other VTE risks. Avoid assuming postpartum eligibility by age alone. Postpartum timing for progestogen or intrauterine methods depends on the method and relevant product and service guidance.
- Other conditions: Current breast cancer treatment rules out hormonal methods under the framework, and completed treatment also warrants specialist discussion. Significant cardiovascular disease, diabetes with vascular involvement and hepatic illness need their own table and product checks. For example, a person treated with tamoxifen who wants an IUD needs discussion of non-hormonal contraception as well as the potential menstrual effects.
Progestogen-only and intrauterine methods
Progestogen-only pills (POPs): Traditional POPs mainly act through cervical mucus, with less consistent ovulation suppression. Their late-pill window is three hours. Desogestrel 75 micrograms has a 12-hour window and primarily suppresses ovulation. Drospirenone 4 mg uses 24 active and four inactive tablets in its licensed regimen, with a 24-hour late threshold for active tablets. Check the actual product and instructions, including how long back-up is needed after a missed pill, which is a separate question from its late threshold. For drospirenone, review renal function and medicines that can raise potassium where relevant.
DMPA injection: The Irish Depo-Provera SmPC specifies 150 mg IM every three months (12–13 weeks). Bleeding changes, weight gain, lower bone mineral density during use and delayed return of ovulation after stopping are counselling points. Review ongoing suitability and risks with prolonged use. For prior VTE, the UKMEC summary lists DMPA category 3 while the implant, POP and LNG-IUD are category 2. Product-specific contraindications still apply, including HPRA advice for contraceptive DMPA with current or previous meningioma.
Etonogestrel implant: The Irish Implanon NXT 68 mg authorisation specifies three years. It suppresses ovulation and thickens cervical mucus. Discuss variable bleeding, drug interactions and return to fertility after removal. It requires trained insertion and removal. A deep or impalpable implant requires location by an appropriate service before removal. HPRA's August 2026 notice also contraindicates desogestrel- and etonogestrel-containing medicines in anyone with a current or previous meningioma. Discontinue the medicine if meningioma is diagnosed.
Intrauterine methods: The copper IUD provides hormone-free contraception and may increase bleeding or dysmenorrhoea. A levonorgestrel IUD thickens cervical mucus and suppresses the endometrium. The 52 mg Mirena can treat idiopathic heavy menstrual bleeding, with different duration rules for contraception, bleeding and endometrial protection. The lower-dose Kyleena and Jaydess are contraceptive devices with separate durations. Discuss expulsion, perforation and symptoms that warrant review. Check pregnancy, infection and the uterine cavity before fitting, and plan postpartum insertion with the relevant service.
| Method | Duration and use | How to compare options |
|---|---|---|
| Combined pill, patch or ring | Replacement schedule depends on the product | Can improve cycle control. Check oestrogen eligibility, interactions and ability to keep to schedule. |
| Progestogen-only pill | Daily. Check formulation-specific late-pill instructions. | An option when oestrogen is unsuitable. Irregular bleeding and missed doses are important to discuss. |
| DMPA IM | 12–13 weeks for Irish Depo-Provera | Avoids daily dosing but can delay fertility return and requires regular reinjection. |
| Etonogestrel implant | Three years for Irish Implanon NXT | Long acting, user-independent and rapidly reversible after removal. Review enzyme-inducing medicines. |
| Levonorgestrel IUD | Eight years for contraception with Mirena 52 mg. Kyleena lasts five and Jaydess three years for contraception. | Long acting. Spotting can occur initially, and the 52 mg device can markedly improve heavy bleeding. Check duration by indication. |
| Copper IUD | Duration depends on the device. Many last five to ten years. | Long acting and hormone free. Discuss existing heavy periods and suitability as emergency contraception. |
Implants and intrauterine devices avoid daily adherence and have high typical-use effectiveness. If a person wants to become pregnant soon after stopping, an injection's delayed return of fertility may influence their choice even when they are otherwise eligible.
Emergency contraception (EC)
Ask about timing of all unprotected sex or contraceptive failure in the cycle, last normal period, usual cycle length, medication, recent hormone use and weight where relevant. Discuss options promptly. A cycle date estimates ovulation and cannot establish whether it happened. Oral EC works by delaying ovulation. The copper IUD can work after ovulation and can remain for ongoing contraception.
Copper IUD
Offer urgent consideration of the copper IUD, the most effective option, and arrange fitting if suitable and acceptable. HSE public information advises fitting within five days after unprotected sex or within five days after earliest ovulation, using the earlier date. The named UK FSRH clinical guideline uses the later of five days from the first unprotected intercourse in a natural cycle and five days from the earliest likely ovulation. With borderline timing, multiple exposures, uncertain cycles or possible eligibility after five days since sex, ask the Irish fitting service urgently to apply its clinical protocol. If fitting may be delayed, consider a timely oral option where appropriate.
Oral choices
| Choice | Authorised timing and dose | Important decisions |
|---|---|---|
| Ulipristal acetate (UPA) | 30 mg once, as soon as possible within 120 hours | Can delay follicular rupture nearer to ovulation than LNG. It is ineffective once ovulation has occurred. Recent progestogen can lessen its effect. The product information advises against use with an enzyme inducer taken in the previous four weeks or in severe asthma treated with oral glucocorticoids. |
| Levonorgestrel (LNG) | 1.5 mg once under usual conditions, as soon as possible within 72 hours for Irish NorLevo | Works by delaying ovulation before the LH surge. For recent enzyme induction the Irish SmPC prefers a copper IUD. If it is unsuitable or declined, the SmPC advises LNG 3 mg within the licensed timing window. |
Under FSRH guidance, if the copper IUD is declined or unsuitable and weight is over 70 kg or BMI over 26 kg/m², consider UPA or double-dose LNG within the relevant timeframe. There is uncertainty about how body size affects oral efficacy and whether doubling LNG improves effectiveness. These thresholds are a named guideline consideration. The Irish NorLevo licence specifies the double dose for recent enzyme induction.
Give a method-specific follow-up plan
Oral EC does not protect against later unprotected intercourse. The FSRH quick-start approach starts a suitable hormonal method immediately after LNG and waits five days after UPA to avoid interfering with ovulation delay. Use condoms or abstain during the wait and until the new method is effective. In this approach a traditional or desogestrel POP needs two days after starting, drospirenone POP and most combined methods seven days, and the combined pill Qlaira nine days. Check the actual method and plan. The EU ellaOne leaflet instead permits starting or continuing hormonal contraception after the dose with barrier cover until the next period. For breastfeeding, the EU ellaOne SmPC advises expressing and discarding for one week, while the January 2025 FSRH statement advises no interruption after one dose. Identify which source the question or clinical setting uses and plan with the prescribing or dispensing service.
Arrange a pregnancy test 21 days after the last unprotected sex when pregnancy cannot be excluded. Seek prompt clinical advice for vomiting within three hours because a replacement dose may be needed. New severe or one-sided pain or a positive test with pain or bleeding warrants prompt assessment for ectopic pregnancy. Offer STI assessment when indicated.
Worked distinction: A person presents after four days and does not want an IUD. Ulipristal is within its authorised window, whereas NorLevo is beyond its authorised window. If the person also took carbamazepine recently, the oral choice changes. Seek urgent copper IUD advice rather than using ulipristal or automatically giving double-dose LNG outside its timing window.
Irish regulation of termination of pregnancy
The Health (Regulation of Termination of Pregnancy) Act 2018, in force since 1 January 2019, provides separate legal grounds. Identify the provision that fits the presentation. Date pregnancy from the first day of the last menstrual period in the ordinary case, with ultrasound when clinically required. Review pain, bleeding and ectopic risk as appropriate.
| Ground | Decision and certification |
|---|---|
| Section 12 — early pregnancy | A medical practitioner examines the patient and certifies the good-faith, reasonable opinion that the pregnancy has not exceeded 12 weeks. At least three days must elapse from the date of that certification or an earlier Section 12 certification. Provide care as soon as possible after that period, while the pregnancy has not exceeded 12 weeks. |
| Section 9 — risk to life or serious harm to health | Two examining medical practitioners, one an obstetrician and the other appropriate to the circumstances, certify that there is a risk to life or of serious harm to health, the fetus has not reached viability, and termination is appropriate to avert the risk. |
| Section 10 — emergency | One examining medical practitioner can act when there is an immediate risk to life or of serious harm to health and termination is immediately necessary to avert that risk. Certify beforehand if practicable. Otherwise certify as soon as possible and no later than three days after the procedure. |
| Section 11 — fetal condition likely to cause death | Two examining medical practitioners, one an obstetrician and one of a relevant specialty, certify a condition likely to cause fetal death before or within 28 days of birth. |
Timing and care in practice
The HSE's date-based example is certification on Monday, with Thursday the earliest treatment date if the other conditions are met. The HSE pathway generally allows a community medical abortion up to nine weeks (63 days) when suitable and moves later care to hospital. Clinical indications or preferences can affect setting. Mifepristone and misoprostol are used in sequence for medical abortion. The treating service advises timing, safety-netting and follow-up. Offer confidential, non-directive information and access to the HSE My Options service where appropriate.
Conscientious objection and continuity
Section 22 applies to doctors, nurses and midwives who object to carrying out or participating in a termination under Sections 9, 11 or 12. They must make the necessary transfer arrangements as soon as possible so the patient can access care. Emergency duties under Section 10 continue to apply. The Medical Council's ninth edition also requires respectful discussion, sufficient information, timely transfer arrangements, and care, support and follow-up after a lawful procedure.
A 36-year-old woman attends the primary care clinic seeking advice regarding reliable contraception. She has two children and does not desire further pregnancies. Her medical history is notable for migraine headaches with visual aura (scintillating scotoma and fortification spectra) occurring twice monthly. She smokes 15 cigarettes per day. Her blood pressure is 126/82 mmHg, and her BMI is 24 kg/m2. She has no personal or family history of venous thromboembolism. Using the CoSRH UKMEC 2025 table, which of the following contraceptive methods is categorized as MEC 4 (unacceptable health risk / absolutely contraindicated) for this patient?
Levonorgestrel-releasing intrauterine system (LNG-IUS / Mirena)
Subdermal etonogestrel implant (Nexplanon)
Combined oral contraceptive pill containing ethinylestradiol and levonorgestrel
Copper intrauterine device (Cu-IUD)
A 22-year-old woman requests emergency contraception at a community pharmacy 102 hours after the only unprotected intercourse in this cycle. The timing of ovulation is uncertain. She takes no medicines, has no history of severe asthma and declines an intrauterine device after counselling. Which oral option is most appropriate under the authorised emergency contraception timing windows?
Levonorgestrel 1.5 mg single oral dose
Mifepristone 200 mg single oral dose
Levonorgestrel 0.75 mg repeated at 12 hours
Ulipristal acetate (EllaOne) 30 mg single oral dose
A 26-year-old woman attends her general practitioner requesting a termination of pregnancy. Her pregnancy is dated at 8 weeks and 2 days, and she has no clinical features that require emergency care. The GP holds a sincere personal conscientious objection to participating in the provision of termination of pregnancy. Under the Health (Regulation of Termination of Pregnancy) Act 2018, which of the following reflects the GP's legal and professional obligations?
The GP may object to participating and must promptly make the transfer arrangements needed for her to access care
The GP must perform the termination procedure because conscientious objection is strictly prohibited in primary care under Irish law
The GP may decline to provide care and has no further legal obligation to refer or assist the patient in accessing alternative care
The GP can only conscientiously object if the pregnancy is beyond 12 weeks gestation or involves a fatal fetal anomaly
Amenorrhoea and subfertility
Amenorrhoea: Exclude pregnancy when possible, including in a patient using contraception. No menarche by age 15 with otherwise normal pubertal development, or absent breast development by age 13, warrants investigation. After previously regular cycles, more than three months without periods warrants assessment. With prior irregular cycles, six months is a common threshold, with earlier investigation if pregnancy or another clinical concern is possible.
Review progression of puberty, cycle pattern, hormonal use, energy intake, exercise, weight changes, medicines and symptoms such as hot flushes, galactorrhoea or androgen excess. After pregnancy testing, TSH, prolactin and FSH with oestradiol can help direct investigation. High FSH with low oestradiol points toward ovarian insufficiency. Low or inappropriately normal FSH with low oestradiol may reflect hypothalamic or pituitary causes. Consider PCOS with androgen excess and ovulatory dysfunction after excluding mimics. In a young person with no menarche and cyclical pain, consider an outflow problem and assess pelvic anatomy.
Subfertility: Assess both partners where applicable. Irish guidance considers referral after more than 12 months of trying below age 36 and after six months from age 36, or earlier when there is a known cause or another reason to expedite assessment. Take a reproductive, medical, medication and sexual history, including timing, previous pelvic infection and surgery, irregular ovulation and possible male factors. Address preconception health and offer support. Semen analysis is an initial investigation. A regular cycle usually suffices as initial evidence of ovulation under Irish guidance. When confirmation is needed, time progesterone to the mid-luteal phase for that person's cycle. Specialist assessment may include ultrasound and evaluation of tubal patency, with the investigation selected according to suspected pelvic pathology. HSE fertility hubs provide eligible patients with assessment and treatment. Assisted reproduction has separate eligibility criteria.
Contraception during testosterone treatment: Ask about pregnancy potential in a private, respectful way, using relevant anatomy and exposure. A person with a uterus and ovaries can still become pregnant during testosterone treatment, even when periods have stopped. Discuss their pregnancy intentions, contraceptive preferences and STI prevention. If a recent exposure could cause an unwanted pregnancy, assess the need for emergency contraception and plan pregnancy testing at the appropriate interval. Discuss future fertility and preservation options with the prescriber before treatment where possible. If pregnancy is suspected or confirmed during testosterone treatment, seek prompt review with the prescriber or treating clinician. See the National Gender Service hormone guidance.
Worked distinction: A 37-year-old with six months of unsuccessful attempts and a history of salpingitis merits early assessment of both partners with consideration of a tubal factor. A 25-year-old with three months of absent previously regular periods after marked weight loss needs assessment of amenorrhoea, beginning with pregnancy testing and evaluation of energy balance and endocrine function, even if they are not trying to conceive.
A 27-year-old trans man with a uterus and ovaries takes testosterone prescribed by a specialist. His periods have stopped. He has a partner who produces sperm and wants to avoid pregnancy. There has been no recent intercourse that could lead to pregnancy. What advice is most appropriate while discussing an ongoing method?
Amenorrhoea confirms protection from pregnancy while he remains on testosterone
Explain that pregnancy is possible and offer a method based on his preferences and medical eligibility
Delay contraception until he has stopped testosterone and menstrual cycles have resumed
Use repeated early pregnancy testing alone to prevent pregnancy
Sections you finish are checked off in the contents.